Business
This week’s Trip Report features announcements on Numinus and Field Trip that paint a story of two different approaches and two different challenges, plus AWAKN expands its scientific board, and more.
Mindset aims to create legal compounds that achieve “equal or greater psychedelic effects and therapeutic benefits” than traditional psilocybin.
In this week’s Trip Report, Berkeley’s new psychedelic research center will focus on spiritual and theological investigations alongside scientific research, and COMPASS files to be listed on the NASDAQ.
Objections to a COMPASS psilocybin synthesis patent have been rejected; Usona’s new efficient technique cannot be patented.
In this week’s Trip Report, England’s National Institute for Health and Care Excellence rejects Spravato, some of the most prominent names in psychedelics will gather for Psych Congress 2020, and more.
David Bronner talks about his company’s 10 year financial commitment to the Multidisciplinary Association for Psychedelic Studies, the importance of supporting MAPS’ nonprofit approach to MDMA research, Dr. Bronner’s “Heal Soul” campaign, and more.
Two companies are developing dissolvable strips to deliver psilocybin, the active ingredient in magic mushrooms.
A Salt Lake City doctor claims his method of using high dose intramuscular injections of ketamine is novel, but other ketamine clinicians say it’s not a new discovery.
Field Trip Collaborates with Jamaican University Researchers to Investigate New Psilocybin Therapies
The focus is on how psilocybin-producing mushrooms may generate a different effect than synthetic psilocybin.
It’s time for the psychedelic community to set high standards, say the cofounders in this exclusive video interview.
